Insider Trading Activity For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Christopher Flint Obrien , Insider of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reportedly Sold 8,734 shares of the company’s stock at an average price of 50 for a total transaction amount of $436,700.00 SEC Form
Insider Trading History For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Analyst Ratings For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
These are 1 Hold Rating, 16 Buy Ratings .
The current consensus rating for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is Buy (Score: 2.94) with a consensus target price of $67.69 , a potential (40.93% upside)
Analyst Ratings History For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- On 11/2/2015 Nomura Boost Price Target of rating Buy with a price target of $34.00 to $43.00
- On 11/22/2016 Citigroup Inc. Initiated Coverage of rating Market Perform with a price target of $55.00
- On 1/19/2017 Deutsche Bank AG Reiterated Rating Buy with a price target of $65.00 to $62.00
- On 1/27/2017 CIBC Upgraded rating Market Perform to Outperform
- On 2/10/2017 ICAP Reiterated Rating Outperform with a price target of $55.00
- On 2/15/2017 Cowen and Company Reiterated Rating Buy
- On 2/16/2017 HC Wainwright Boost Price Target of rating Positive with a price target of $80.00 to $100.00
Recent Trading Activity for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Shares of Neurocrine Biosciences, Inc. closed the previous trading session at 48.03 down -1.43 -2.89% with 670,636 shares trading hands.